Dr. Reddy`s Laboratories Receivables

The latest receivables for RDY is $99B as of March 2026. That compares with $110B in the prior-year period — down 9.6% year over year. Investors often review this figure alongside Dr. Reddy`s Laboratories's historical trend and sector peers before judging valuation or financial health.

Over the past year, RDY's receivables moved from $110B to $99B — a 9.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dr. Reddy`s Laboratories's operating scale or balance-sheet position.

A receivables figure of $99B for RDY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RDY's receivables ($99B), review year-over-year change from $110B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Dr. Reddy`s Laboratories's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.